Drug Profile
Research programme: chemokine antagonists - Evolutec
Latest Information Update: 19 Mar 2008
Price :
$50
*
At a glance
- Originator Evolutec
- Class
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 11 Jan 2002 Preclinical development for Autoimmune disorders in United Kingdom (Unknown route)